WO2014031586A3 - Methods for treating cardiovascular diseases - Google Patents

Methods for treating cardiovascular diseases Download PDF

Info

Publication number
WO2014031586A3
WO2014031586A3 PCT/US2013/055697 US2013055697W WO2014031586A3 WO 2014031586 A3 WO2014031586 A3 WO 2014031586A3 US 2013055697 W US2013055697 W US 2013055697W WO 2014031586 A3 WO2014031586 A3 WO 2014031586A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
subject
adipose tissue
lipoxygenase
flap
Prior art date
Application number
PCT/US2013/055697
Other languages
French (fr)
Other versions
WO2014031586A2 (en
Inventor
Naser Ahmadi
Matthew BUDOFF
Raymond Tabibiazar
Fred CRAVES
Tilmann Brotz
Original Assignee
Tallikut Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tallikut Pharmaceuticals, Inc. filed Critical Tallikut Pharmaceuticals, Inc.
Publication of WO2014031586A2 publication Critical patent/WO2014031586A2/en
Publication of WO2014031586A3 publication Critical patent/WO2014031586A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is based in part on the discovery that an inhibitor of the 5-lipoxygenase pathway (for example, a 5-lipoxygenase inhibitor or a 5-lipoxygenaseactivating protein (FLAP) inhibitor) can preserve and improve cardiac function, mitigate cardiac dysfunction, as well as reduce epicardial adipose tissue and/or pericardial adipose tissue in a subject suffering from a cardiovascular disease. Accordingly, the present invention provides methods for mitigating cardiac dysfunction in a subject in need thereof by administering to the subject a composition comprising a 5-lipoxygenase inhibitor or a FLAP inhibitor. The present invention further provides methods for preserving and/or improving cardiac function in a subject in need thereof by administering to the subject a composition comprising a 5-lipoxygenase inhibitor or a FLAP inhibitor. In addition, the present invention provides methods for reducing epicardial adipose tissue and/or pericardial adipose tissue in a subject in need thereof by administering to the subject a composition comprising a 5-lipoxygenase inhibitor or a FLAP inhibitor.
PCT/US2013/055697 2012-08-20 2013-08-20 Methods for treating cardiovascular diseases WO2014031586A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261691064P 2012-08-20 2012-08-20
US61/691,064 2012-08-20

Publications (2)

Publication Number Publication Date
WO2014031586A2 WO2014031586A2 (en) 2014-02-27
WO2014031586A3 true WO2014031586A3 (en) 2015-07-16

Family

ID=50150472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/055697 WO2014031586A2 (en) 2012-08-20 2013-08-20 Methods for treating cardiovascular diseases

Country Status (1)

Country Link
WO (1) WO2014031586A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906145A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
CN105078957B (en) * 2014-05-04 2017-11-21 中国医学科学院基础医学研究所 Trihydroxyflavone is preparing the purposes in being used to treat or prevent the medicine of abdominal aneurvsm
EP3677259A1 (en) * 2019-01-07 2020-07-08 Mosaiques Diagnostics And Therapeutics AG Use of arachidonyl trifluoromethyl ketone

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035741A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US20060004040A1 (en) * 2002-08-26 2006-01-05 Jilly Evans Method for the prevention and/or treatment of atherosclerosis
WO2007056021A2 (en) * 2005-11-04 2007-05-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2008067566A1 (en) * 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
WO2009002746A1 (en) * 2007-06-22 2008-12-31 Decode Genetics Ehf. Dosing schedules of leukotriene synthesis inhibitors for human therapy
US20090227638A1 (en) * 2005-03-23 2009-09-10 Marc Blouin Novel Pharmaceutical Compounds
US20090291981A1 (en) * 2008-05-23 2009-11-26 Amira Pharmaceuticals, Inc. 5-Lipoxygenase-Activating Protein Inhibitor
US20100075934A1 (en) * 2007-10-26 2010-03-25 Amira Pharmaceuticals, Inc. 5-lipoxygenase activating protein (flap) inhibitor

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004040A1 (en) * 2002-08-26 2006-01-05 Jilly Evans Method for the prevention and/or treatment of atherosclerosis
WO2004035741A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US20090227638A1 (en) * 2005-03-23 2009-09-10 Marc Blouin Novel Pharmaceutical Compounds
WO2007056021A2 (en) * 2005-11-04 2007-05-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2008067566A1 (en) * 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
WO2009002746A1 (en) * 2007-06-22 2008-12-31 Decode Genetics Ehf. Dosing schedules of leukotriene synthesis inhibitors for human therapy
US20100075934A1 (en) * 2007-10-26 2010-03-25 Amira Pharmaceuticals, Inc. 5-lipoxygenase activating protein (flap) inhibitor
US20090291981A1 (en) * 2008-05-23 2009-11-26 Amira Pharmaceuticals, Inc. 5-Lipoxygenase-Activating Protein Inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALLEN, S ET AL.: "Differential Leukotriene Constrictor Responses in Human Atherosclerotic Coronary Arteries.", CIRCULATION., vol. 97, 23 June 1998 (1998-06-23), pages 2406 - 2413 *

Also Published As

Publication number Publication date
WO2014031586A2 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
WO2011057249A3 (en) Treatment of heart disease
BR112015012781A2 (en) composition comprising biological control agents
CA2871471C (en) Dna-pk inhibitors
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
WO2011057251A3 (en) Treatment of heart disease
MX342409B (en) Treatment of cardiac conditions.
WO2013049770A3 (en) Methods of treating cancer
WO2011083150A3 (en) Obesity small molecules
WO2015095354A3 (en) Compositions and methods for treating fatty tissue buildup
BR112015029926A2 (en) combination of active agents for skin aging treatment
SG10201909382UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
PH12017550090A1 (en) Composition for improving or preventing nonalcoholic fatty liver
WO2014031586A3 (en) Methods for treating cardiovascular diseases
WO2015076717A3 (en) Mscs in the treatment of cardiac disorders
BR112015022044A2 (en) a method of providing ocular neutroprotection
WO2015074010A3 (en) Compositions and methods for cardiac regeneration
WO2012019086A3 (en) Inhibition of lar phosphatase to enhance therapeutic angiogenesis
WO2012045974A3 (en) Cosmetic use of a tropaeolum majus extract as an active principle for promoting the oxygenation of skin tissue
EA201791525A2 (en) CONNECTIONS FOR THE TREATMENT OF THE BLOCADE OF REMIELINIZATION IN DISEASES RELATED TO THE EXPRESSION OF THE PROTECTIVE PROTEIN
EA201590522A1 (en) METHODS OF INTRODUCTION OF RIFAXIMINE TO REDUCE WEIGHT AND TREAT OBESITY
MX2017014991A (en) Beta-casein a2 and antioxidant capacity.
WO2019017677A3 (en) Composition comprising citral as effective ingredient for exhibiting effect of muscle strengthening, muscle enhancement, muscle differentiation, muscle regeneration, or sarcopenia suppression
NZ723206A (en) A method of improving liver function
BR112013003149A2 (en) panthenyl docosahexaenoate and its use for the treatment and prevention of cardiovascular disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13831464

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13831464

Country of ref document: EP

Kind code of ref document: A2